These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Immune Checkpoint Inhibition-Does It Cause Rheumatic Diseases? Mechanisms of Cancer-Associated Loss of Tolerance and Pathogenesis of Autoimmunity. Thanarajasingam U; Abdel-Wahab N Rheum Dis Clin North Am; 2020 Aug; 46(3):587-603. PubMed ID: 32631606 [TBL] [Abstract][Full Text] [Related]
9. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles. Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392 [TBL] [Abstract][Full Text] [Related]
10. Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis. Kumar P; Saini S; Prabhakar BS Semin Cancer Biol; 2020 Aug; 64():29-35. PubMed ID: 30716481 [TBL] [Abstract][Full Text] [Related]
20. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]